Abstract:Objective To screen and preliminarily identify differentially expressed genes (DEGs) in benign prostatic fibrous hyperplasia, and to discover novel gene fragments involved in the occurrence of benign prostatic fibrous hyperplasia, thereby providing potential target gene loci and biomarkers for the diagnosis and treatment of benign prostatic fibrous hyperplasia.Methods Prostate tissues were collected from 14 patients after transurethral plasma kinetic prostatectomy. According to the pathological diagnosis, all the specimens were divided into fibrous group and nodular group. The specimens were cryopreserved, and the total RNA was extracted respectively to construct a transcriptome library. Through the second-generation high-throughput sequencing, the mRNA in the two groups was quantified and the DEGs between the groups were determined. Then Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction (PPI) analyses based on the DEGs were carried out.Results A total of 1598 DEGs were found between the two groups. As compared with the nodular group, there were 1,063 up-regulated genes and 535 down-regulated genes in the fibrous group. The GO functional enrichment analysis showed that DEGs were enriched in biological processes such as the ion transport, cellular adhesion, and extracellular matrix organization, molecular functions such as the proximal promoter DNA-binding transcription activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding, DNA-binding transcription activator activity, and signaling receptor binding, and cellular components such as integral component of membrane, extracellular region, and plasma membrane. In addition, KEGG pathway analysis exhibited that DEGs were mainly enriched in extracellular matrix-receptor interaction and cytokine-cytokine receptor interaction. The construction of PPI network of DEGs identified 10 hub genes and found that PPBP, OPRM1 and GAL were up-regulated in benign prostatic fibrous hyperplasia.Conclusions PPBP, OPRM1, GAL and other DEGs are involved in the occurrence and development of benign prostatic fibrous hyperplasia, and can be established as potential biomarkers for treating benign prostatic fibrotic hyperplasia and monitoring the disease activity.